Related Experiment Video

Updated: May 9, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

A new age for vaccine therapy in renal cell carcinoma

Sumanta K Pal1, Adriana Hu, Robert A Figlin

  • 1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. spal@coh.org

Cancer Journal (Sudbury, Mass.)
|July 23, 2013
PubMed

Insights

Novel vaccine therapies are emerging as a promising new strategy for metastatic renal cell carcinoma (mRCC) as current targeted treatments reach their limits. Research explores various vaccine types and their potential to overcome treatment plateaus.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Targeted therapies, such as those inhibiting vascular endothelial growth factor receptor, have been the standard for metastatic renal cell carcinoma (mRCC) drug development.
  • The efficacy of current targeted treatments for mRCC is approaching a plateau, necessitating the exploration of alternative therapeutic strategies.
  • Vaccine-based therapies represent a novel approach to address the limitations of existing mRCC treatments.

Purpose of the Study:

  • To review the current landscape of vaccine-based therapies being investigated for metastatic renal cell carcinoma (mRCC).
  • To detail the distinct mechanisms of action employed by various mRCC vaccines.
  • To discuss the challenges associated with the clinical implementation of these novel vaccine therapies.

Main Methods:

  • Review of current vaccine-based therapies under investigation for metastatic renal cell carcinoma (mRCC).
  • Description of specific vaccine examples, including AGS-003 (autologous dendritic cell vaccine), TG4010 (poxvirus vaccine targeting MUC1), and IMA901 (peptide-based vaccine).
  • Analysis of the technological platforms used for vaccine antigen identification, such as mass spectroscopy and RNA expression analysis.

Main Results:

  • Several distinct vaccine-based therapies are in development for mRCC, each with unique antigen targets and mechanisms.
  • Examples include patient-specific antigen vaccines (AGS-003), vaccines targeting tumor-associated glycoproteins (TG4010), and multi-peptide vaccines (IMA901).
  • The development of these vaccines involves advanced biotechnological platforms for antigen discovery and validation.

Conclusions:

  • Vaccine-based therapies offer a promising new avenue for treating metastatic renal cell carcinoma (mRCC) beyond current targeted approaches.
  • Understanding the diverse mechanisms and antigen targets of these vaccines is crucial for their development.
  • Significant challenges remain for clinical implementation, including cost, optimal combination with existing treatments, and sequencing strategies.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...